AstraZeneca and Bristol-Myers Squibb Discuss Potential $400 Billion Pharmaceutical Merger
The Financial Times reported after market close that pharmaceutical giants AstraZeneca and Bristol-Myers Squibb (BMS) are in talks about a possible merger. AstraZeneca is valued at £196 billion ($264 billion) on the London Stock Exchange, while BMS trades at $133 billion on the New York Stock Exchange. If the merger is approved and market values hold, the combined company could be worth around $400 billion, making it one of the largest deals in the pharmaceutical sector.
Both companies have seen strong stock performance recently, with BMS shares rising 44% and AstraZeneca 13% over the past year. However, antitrust regulators may pose challenges due to overlapping operations, especially in oncology and cardiology. AstraZeneca’s cancer drugs generated $25 billion of its $59 billion revenue in 2025, while BMS reported $48 billion in revenue from cardiology, hematology, and oncology in the same year.
BMS faces patent expirations on key products like the blood thinner Eliquis, which brought in $14 billion in revenue, and the cancer immunotherapy Opdivo. It is focusing on new drugs such as Cobenfy for schizophrenia, acquired through a $14 billion purchase of the company Kronos, founded by former Israeli entrepreneur Dafna Zohar. AstraZeneca recently listed on the NYSE to strengthen its U.S. market presence and has expanded manufacturing in the U.S., partly due to pressure from former President Donald Trump.
A merger could accelerate AstraZeneca’s U.S. footprint and help BMS reduce reliance on uncertain product pipelines. Both companies have made significant acquisitions in recent years but no major mergers. Neither company has commented yet on the merger talks, and their stock prices have not reacted to the news.
Summary: AstraZeneca and Bristol-Myers Squibb are reportedly negotiating a potential merger that could create a $400 billion pharmaceutical powerhouse, combining strong oncology and cardiology portfolios amid regulatory scrutiny and patent challenges. The deal would significantly boost AstraZeneca’s U.S. presence and help BMS diversify its product pipeline.
